Currently,various clinical treatment methods struggle to halt the rapid progression of common acute liver failure.To address this issue,significant advancements in stem cell derivatives and bioactive hydrogels in rege...Currently,various clinical treatment methods struggle to halt the rapid progression of common acute liver failure.To address this issue,significant advancements in stem cell derivatives and bioactive hydrogels in regenerative medicine have been utilized.A bioactive hydrogel with good tissue adhesion,CCO/HGF@EV,has been designed by incorporating cytokine hepatocyte growth factor(HGF),which plays a major role in the early regenerative phase of the liver,into stem cell-derived exosomal vesicles(EV)through electroporation.Under ultrasonic guidance,CCO/HGF@EV is administered near the liver,adhering firmly and degrading over three days to release HGF@EV.Through a series of rigorous experiments,it was confirmed that the abundant anti-inflammatory and regenerative cytokines in HGF@EV significantly reduced reactive oxygen species(ROS)during the acute phase of liver failure,alleviated hepatocyte apoptosis,decreased inflammatory damage and necrosis of liver tissue,and significantly promoted the regeneration and repair of liver parenchymal cells and vascular tissues.Additionally,the release of HGF after EV fusion with hepatocytes synergistically enhanced the regeneration of liver cells during the acute phase,thereby stabilizing liver function.This hydrogel,with its powerful therapeutic effects,forms a protective layer over the liver.It holds great potential for advancing research in tissue engineering and regenerative medicine and has significant clinical translational value.展开更多
基金supported by the Fellowship of China Postdoctoral Science Foundation(No.2023M732299)。
文摘Currently,various clinical treatment methods struggle to halt the rapid progression of common acute liver failure.To address this issue,significant advancements in stem cell derivatives and bioactive hydrogels in regenerative medicine have been utilized.A bioactive hydrogel with good tissue adhesion,CCO/HGF@EV,has been designed by incorporating cytokine hepatocyte growth factor(HGF),which plays a major role in the early regenerative phase of the liver,into stem cell-derived exosomal vesicles(EV)through electroporation.Under ultrasonic guidance,CCO/HGF@EV is administered near the liver,adhering firmly and degrading over three days to release HGF@EV.Through a series of rigorous experiments,it was confirmed that the abundant anti-inflammatory and regenerative cytokines in HGF@EV significantly reduced reactive oxygen species(ROS)during the acute phase of liver failure,alleviated hepatocyte apoptosis,decreased inflammatory damage and necrosis of liver tissue,and significantly promoted the regeneration and repair of liver parenchymal cells and vascular tissues.Additionally,the release of HGF after EV fusion with hepatocytes synergistically enhanced the regeneration of liver cells during the acute phase,thereby stabilizing liver function.This hydrogel,with its powerful therapeutic effects,forms a protective layer over the liver.It holds great potential for advancing research in tissue engineering and regenerative medicine and has significant clinical translational value.
